Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ASTELLAS PHARMA EUROPE B.V.

Home Clinical Trial Sponsors and OrganizationsASTELLAS PHARMA EUROPE B.V.

ASTELLAS PHARMA EUROPE B.V.

CALLE SERRANO, 110 - 4 IZQUIERDA, Madrid, Spain

Also known as:

yamanouchi europe

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

462

368 active

Approvals

82

Total approvals

Agencies

5

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

240

52.0%

Phase 3

14

3.0%

Phase 2

13

2.8%

Phase 4

3

0.7%

Trial Status Distribution

Active, not recruiting

368

79.7%

Completed

89

19.3%

Terminated

4

0.9%

Withdrawn

1

0.2%

Clinical Trials

Trials sponsored by this organization (462)

Study to investigate the effect and safety of ASP8302 in the treatment of subjects with an underactive bladder

Active, not recruiting

Jun 2019163 participants

A Study of ASP8302 in Participants With Underactive Bladder

Nov 2018135 participants

Study to investigate the effect and safety of ASP8302 in the treatment of subjects with an underactive bladder

Active, not recruiting

Oct 2018163 participants

Study to investigate the effect and safety of ASP8302 in the treatment of subjects with an underactive bladder

Active, not recruiting

Aug 2018163 participants

Study to investigate the effect and safety of ASP8302 in the treatment of subjects with an underactive bladder

Active, not recruiting

Aug 2018163 participants

Study to investigate the effect and safety of ASP8302 in the treatment of subjects with an underactive bladder

Active, not recruiting

Jul 2018163 participants

A study to investigate how effective and safe the study medication ‘mirabegron’ is and how long it stays in the body in children and adolescents aged 3 to less than 18 years with symptoms of an overactive bladder with a neurologic cause.

Active, not recruiting

Apr 201863 participants

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

Nov 2017102 participants

Page 1 of 58

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

29

Approvals

EMA

European Medicines Agency

20

Approvals

PHILIPPINES

Philippines FDA

3

Approvals

SFDA

Saudi Food and Drug Authority

3

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

27

Approvals

Recent Approvals

OMNIC OCAS 0,4 MG COMPRIMIDOS DE LIBERACION PROLONGADA RECUBIERTOS CON PELICULA

VESICARE 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

OMNIC OCAS 0,4 MG COMPRIMIDOS DE LIBERACION PROLONGADA RECUBIERTOS CON PELICULA

Tacrolimus Granules

Tacrolimus Granules

Zolbetuximab for Injection

12 October 2024

News

No news articles found

On this page

Overview
Clinical Trials462
Approvals82
News

Back to Organizations